Reversal of subtype-selectivity and function by the introduction of a para-benzamidyl substituent to N-cyclopropylmethyl nornepenthone.

[1]  B. Roth,et al.  Structures of the entire human opioid receptor family , 2023, Cell.

[2]  Samuel T. Slocum,et al.  Structure-based design of bitopic ligands for the µ-opioid receptor , 2022, Nature.

[3]  Xi Cheng,et al.  Molecular recognition of morphine and fentanyl by the human μ-opioid receptor , 2022, Cell.

[4]  Wei-Chang Fu,et al.  SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity. , 2022, Journal of medicinal chemistry.

[5]  G. Skiniotis,et al.  Structure‐Based Evolution of G Protein‐Biased μ‐Opioid Receptor Agonists , 2022, bioRxiv.

[6]  B. Armoon,et al.  Mental health status, health service utilization, drug use behaviors associated with non-fatal overdose among people who use illicit drugs: A meta-analysis , 2021, Journal of Substance Use.

[7]  Joseph M. Paggi,et al.  Insights into distinct signaling profiles of the µOR activated by diverse agonists , 2022, Nature Chemical Biology.

[8]  M. Karamouzian,et al.  Mental disorder and opioid overdose: a systematic review , 2021, Social Psychiatry and Psychiatric Epidemiology.

[9]  M. J. Robertson,et al.  Structure Determination of Inactive-State GPCRs with a Universal Nanobody , 2021, bioRxiv.

[10]  Wei-Chang Fu,et al.  Discovery of an M-Substituted N-Cyclopropylmethyl-7α-phenyl-6,14-endoethanotetrahydronorthebaine as a Selective, Potent, and Orally Active κ-Opioid Receptor Agonist with an Improved Central Nervous System Safety Profile. , 2021, Journal of medicinal chemistry.

[11]  Wei-Chang Fu,et al.  Discovery, Structure-Activity Relationship, and Mechanistic Studies of 1-((3R,4S)-3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as a Novel Potent Analgesic. , 2021, Journal of Medicinal Chemistry.

[12]  R. M. Krausz,et al.  The opioid overdose crisis as a global health challenge , 2021, Current opinion in psychiatry.

[13]  M. Manzar,et al.  Emerging Challenges in COVID-19 With Substance Use Disorders , 2021, Addictive Disorders & Their Treatment.

[14]  L. Manchikanti,et al.  COVID-19 and the Opioid Epidemic: Two Public Health Emergencies That Intersect With Chronic Pain , 2021, Pain and Therapy.

[15]  S. Shoptaw,et al.  The opioid crisis and HIV in the USA: deadly synergies , 2021, The Lancet.

[16]  Yan Zhang,et al.  Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators , 2020, Journal of Computer-Aided Molecular Design.

[17]  N. Volkow,et al.  The Changing Opioid Crisis: development, challenges and opportunities , 2020, Molecular Psychiatry.

[18]  J. Bell,et al.  Medication Treatment of Opioid Use Disorder , 2020, Biological Psychiatry.

[19]  D. Selley,et al.  Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators. , 2019, Journal of medicinal chemistry.

[20]  Wei Li,et al.  Discovery of a highly selective and potent kappa opioid receptor agonist from N-cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydro- northebaines with reduced central nervous system (CNS) side effects navigated by the message-address concept. , 2019, Journal of medicinal chemistry.

[21]  R. Stevens,et al.  Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists , 2019, Science Advances.

[22]  S. Naveed,et al.  A Review of Samidorphan: A Novel Opioid Antagonist , 2019, Cureus.

[23]  N. Volkow,et al.  Prevention and Treatment of Opioid Misuse and Addiction: A Review , 2019, JAMA psychiatry.

[24]  D. Selley,et al.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands. , 2019, Journal of medicinal chemistry.

[25]  D. Selley,et al.  Structure-Activity Relationship Studies of 6α- and 6β-Indolylacetamidonaltrexamine Derivatives as Bitopic Mu Opioid Receptor Modulators and Elaboration of the "Message-Address Concept" To Comprehend Their Functional Conversion. , 2018, ACS chemical neuroscience.

[26]  G. Walker.  The opioid crisis: a 21st century pain. , 2018, Drugs of today.

[27]  Ryan T. Strachan,et al.  Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor , 2018, Cell.

[28]  Wei-Chang Fu,et al.  The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities. , 2017, ACS chemical neuroscience.

[29]  Stephen M. Husbands,et al.  Structural insights into μ-opioid receptor activation , 2015, Nature.

[30]  G. Kellogg,et al.  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands. , 2015, Bioorganic & medicinal chemistry.

[31]  E. Bullmore,et al.  The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours , 2014, Psychopharmacology.

[32]  D. Selley,et al.  Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents. , 2012, Journal of medicinal chemistry.

[33]  Aashish Manglik,et al.  Structure of the δ-opioid receptor bound to naltrindole , 2012, Nature.

[34]  L. Pardo,et al.  Crystal structure of the μ-opioid receptor bound to a morphinan antagonist , 2012, Nature.

[35]  Bryan L. Roth,et al.  Structure of the human kappa opioid receptor in complex with JDTic , 2012, Nature.

[36]  Yun Tang,et al.  Synthesis and evaluation of κ-opioid receptor agonistic activity and antinociceptive effect of novel morphine analogues, 7α-phenyl-6α,14α-endo-etheno-tetrahydrothebaine with substituted o-, m- and p-amino group , 2011, Medicinal Chemistry Research.

[37]  K. Rice,et al.  Identification of a novel “almost neutral” μ‐opioid receptor antagonist in CHO cells expressing the cloned human μ‐opioid receptor , 2010, Synapse.

[38]  D. Selley,et al.  Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. , 2009, Journal of medicinal chemistry.

[39]  Y. Long,et al.  LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. , 2008, European journal of pharmacology.

[40]  W. Schmidt,et al.  Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. , 2001, American journal of surgery.

[41]  D. Ferguson,et al.  Transformation of a κ-Opioid Receptor Antagonist to a κ-Agonist by Transfer of a Guanidinium Group from the 5‘- to 6‘-Position of Naltrindole , 2001 .

[42]  T. Sumpter,et al.  Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine. , 2000, The Journal of pharmacology and experimental therapeutics.

[43]  P. Portoghese,et al.  5'-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist , 2000 .

[44]  B. Roques,et al.  μ-Opioid receptor specific antagonist cyprodime: characterization by in vitro radioligand and [35S]GTPγS binding assays , 1999 .

[45]  H. Nagase,et al.  Pharmacological properties of TRK-820 on cloned μ-, δ- and κ-opioid receptors and nociceptin receptor , 1999 .

[46]  J. Woods,et al.  Clocinnamox: a novel, systemically-active, irreversible opioid antagonist. , 1992, The Journal of pharmacology and experimental therapeutics.

[47]  P. Portoghese,et al.  Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. , 1990, Journal of medicinal chemistry.

[48]  Kunjea Kim,et al.  Synthesis of the New Thebaine Derivatives by the Diels-Alder Reaction with Northebaine , 1989 .

[49]  J. P. Gonzalez,et al.  Naltrexone , 1988, Drugs.

[50]  P. Portoghese,et al.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. , 1988, Journal of medicinal chemistry.

[51]  D. Weidler,et al.  Nalmefene: Safety and Kinetics After Single and Multiple Oral Doses of a New Opioid Antagonist , 1987, Journal of clinical pharmacology.

[52]  T. Gal,et al.  Prolonged blockade of opioid effect with oral nalmefene , 1986, Clinical pharmacology and therapeutics.

[53]  D. L. Larson,et al.  Opioid receptor binding characteristics of the non-equilibrium μ antagonist, β-funaltrexamine (β-FNA)☆ , 1985 .

[54]  D. Sessler,et al.  Opioid-Induced Bowel Dysfunction , 2012, Drugs.

[55]  Yun Tang,et al.  Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton. , 2010, Bioorganic & medicinal chemistry letters.

[56]  P. M. Goodrich.  Naloxone hydrochloride: a review. , 1990, AANA journal.